Entry38.38→Now38.98
Minervini holds $TEVA long, working position Open original source
TEVA Teva Pharmaceutical Industries Limited Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Entry38.72→Now38.98
Teva transformation, pipeline drive valuation. Open original source
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
15:09
Sep 15
Sep 15
Minervini holds $TEVA long, working position
Discloses an existing long in Teva that is performing well and being held above stops, kept as one of the two profitable positions in a reduced-exposure portfolio during market weakness.
MED
22:17
Sep 14
Sep 14
Teva transformation, pipeline drive valuation.
Teva is moving from ADS to ordinary shares to broaden U.S. investor access, part of a multi-year transformation from a pure generics company to a world-class pharma with a $13B late-stage pipeline; he expects the strategy to drive long-term top- and bottom-line growth and higher valuation as they execute.
HIGH
20:10
Aug 31
Aug 31
Teva reports that drug-pricing negotiations remain active and anchored in all four of Trump's.
Teva reports that drug-pricing negotiations remain active and anchored in all four of Trump's priorities, with final terms still confidential.
20:10
Aug 31
Aug 31
Teva and the Trump administration announce intent to reach an agreement on affordable medicines.
Teva and the Trump administration announce intent to reach an agreement on affordable medicines and U.S. supply-chain security with Teva offering a dedicated API reserve and continued manufacturing investment.
15:42
Aug 09
Aug 09
Generic fertility drug makers seen as beneficiaries
Buy generic drug makers TEVA, Sandoz (SDZNY), and Hikma (HKMPY) as fertility drug generics see potential demand uplift from increased public awareness around egg freezing; speculative thematic call.
LOW
22:07
Jul 29
Jul 29
Long Teva, pipeline and volume growth
Teva delivered a strong Q2, raised guidance across all metrics, and sees upside in its key products. There is a large unmet patient need that will drive volume growth even as Medicare pricing rules impact pricing. The pipeline includes a Tourette's syndrome treatment with an expected approval around end of Q2 next year, and the company is well-positioned to maximize these opportunities.
LOW
04:12
Feb 18
Feb 18
Reports Druckenmiller trimmed position
Reports Druckenmiller's Duquesne trimmed position, no directional view from speaker.
MED
20:41
Feb 03
Feb 03
Teva benefits from generic semaglutide but has run
Author holds Teva and likes it as a generic semaglutide winner, though he notes the stock has ripped 70% and is now less attractive. The mechanism is generic semaglutide launches in Canada, Brazil, and India as Novo Nordisk's patents expire. Main risk is that much of the price move has already happened.
HIGH
00:44
Jan 29
Jan 29
Teva pipeline drives growth turnaround.
Teva's pivot to growth is working: AUSTEDO peak sales are now $3 billion versus prior $1.4 billion estimates and closed 2025 at $2.26 billion; migraine injectable Ajovy grew 30% and can reach $1 billion; the schizophrenia franchise is strong with long-acting injectables, Uzedy up 63%, and a long-acting olanzapine launch coming. Teva expects four product launches in five years, seven innovative milestones in 2026, and the market underestimates its science.
HIGH
23:43
Jan 13
Jan 13
Teva pivots to biopharma pipeline growth.
Teva is transforming from a pure generics company to a biopharma company; branded/innovation sales should outpace generics by 2030 and the late-stage pipeline could generate nearly $12B by 2035. Existing innovative products are growing over 30%, multiple 2026 data readouts and launches are coming, and the long-acting olanzapine schizophrenia franchise could launch around late Q3/early Q4.
HIGH
About TEVA Investor Commentary
Across the available history and selected sources, Buzzberg tracks TEVA (Teva Pharmaceutical Industries Limited) across 7 sources: 7 bullish vs 0 bearish calls from 6 authors. Historical directional balance: 70% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 10 total trade ideas tracked. Past 7 days, before deduplication: 2 bullish. Latest voices: Mark Minervini, Richard Francis, FirstSquawk.